Literature DB >> 28861615

About MET expression and other biomarkers in non-small cell lung cancer.

Laetitia Lambros1, Isabelle Quintin-Roué1, Briac Guibourg1, Arnaud Uguen2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28861615     DOI： 10.1007/s00428-017-2229-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  3 in total

Review 1.  Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Authors:  Alexander Drilon; Federico Cappuzzo; Sai-Hong Ignatius Ou; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2016-10-26       Impact factor: 15.609

2.  MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC.

Authors:  William Sterlacci; Michael Fiegl; Mathias Gugger; Lukas Bubendorf; Spasenija Savic; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2017-05-20       Impact factor: 4.064

3.  Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  David R Spigel; Thomas J Ervin; Rodryg A Ramlau; Davey B Daniel; Jerome H Goldschmidt; George R Blumenschein; Maciej J Krzakowski; Gilles Robinet; Benoit Godbert; Fabrice Barlesi; Ramaswamy Govindan; Taral Patel; Sergey V Orlov; Michael S Wertheim; Wei Yu; Jiping Zha; Robert L Yauch; Premal H Patel; See-Chun Phan; Amy C Peterson
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.